One study showed that gliomas with IDH1 and IDH2 mutation downregulate expression of NKG2D ligands (ULBP1 and ULBP3) by affecting DNA methylation, thus escaping NKs immune surveillance 148. This evidence concerns the gene KLRK1 and central nervous system cancer.